MARKET

HCM

HCM

HUTCHMED (China) Limited
NASDAQ

Real-time Quotes | Nasdaq Last Sale

26.48
-0.27
-1.01%
After Hours: 26.48 0 0.00% 16:00 05/18 EDT
OPEN
26.78
PREV CLOSE
26.75
HIGH
26.80
LOW
25.62
VOLUME
185.36K
TURNOVER
--
52 WEEK HIGH
37.00
52 WEEK LOW
19.77
MARKET CAP
3.94B
P/E (TTM)
-293.8957
1D
5D
1M
3M
1Y
5Y
Save the date: HUTCHMED to Host Company Update on R&D, Commercial and ASCO Data For Analysts and Investors
HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM) today announces that it will host a virtual investor update event on Wednesday, May 26, 2021. Members of the senior management team will provide updates on product launches in China, preparations for ...
GlobeNewswire · 1d ago
Thymoma (Thymic Epithelial Tumor) Market SWOT Analysis by Key Players: Novartis, Merck, Bayer
May 11, 2021 (Market Insight Reports) -- A new research document is added in HTF MI database of 156 pages, titled as ‘Thymoma (Thymic Epithelial Tumor) –...
Market Insight Reports · 05/11 05:14
HUTCHMED to Attend Upcoming Investor Conferences
HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM) today announces that Mr Christian Hogg, Chief Executive Officer of HUTCHMED, will participate in a virtual fireside chat at the Bank of America 2021 Health Care Conference on Tuesday, May 11, 2021 at ...
GlobeNewswire · 05/07 11:00
BRIEF-Hutchison China MediTech Says Surufatinib FDA Rolling NDA Submission Completed
reuters.com · 05/04 08:46
Change of Company Name
HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., May 04, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (Nasdaq/AIM: HCM), formerly known as Hutchison China MediTech Limited, announces that, further to its “Results of Annual General Meeting” announcem...
GlobeNewswire · 05/04 07:00
BRIEF-Hutchmed Completes Rolling Submission Of NDA To U.S. FDA For Surufatinib For The Treatment Of Advanced Neuroendocrine Tumors
reuters.com · 05/03 12:21
HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors
HONG KONG and SHANGHAI, China and FLORHAM PARK, May 03, 2021 (GLOBE NEWSWIRE via COMTEX) -- HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 03,...
GlobeNewswire · 05/03 11:00
Hutchison China MediTech Completes NDA Submission to FDA for Surufatinib to Treat Advanced Neuroendocrine Tumors
MT Newswires · 05/03 08:23
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of HCM. Analyze the recent business situations of HUTCHMED (China) Limited through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average HCM stock price target is 40.01 with a high estimate of 45.00 and a low estimate of 29.91.
EPS
Institutional Holdings
Institutions: 169
Institutional Holdings: 53.95M
% Owned: 36.23%
Shares Outstanding: 148.90M
TypeInstitutionsShares
Increased
54
3.76M
New
14
330.79K
Decreased
41
1.77M
Sold Out
5
55.55K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.07%
Pharmaceuticals & Medical Research
+0.07%
Key Executives
Chairman/Director
Simon To
Chief Executive Officer/Executive Director/IR Contact Officer
Christian Hogg
Chief Financial Officer/Executive Director
Chig Fung Cheng
Executive Director
Weiguo Su
Secretary/Non-Executive Director
Edith Shih
Non-Executive Director
Dan Eldar
Non-Executive Independent Director
Paul Carter
Non-Executive Independent Director
Karen Ferrante
Non-Executive Independent Director
Graeme Jack
Non-Executive Independent Director
Shu Kam Mok
No Data
About HCM
HUTCHMED China Ltd, formerly Hutchison China Meditech Ltd, is an investment holding company principally engaged in the manufacturing and sale of drugs. Along with subsidiaries, the Company operates its business through two segments. The Oncology and Immunology segment is engaged in all activities related to oncology and immunology including sales, marketing, manufacturing and research and development with respect to drugs and drug candidates. The Other Ventures segment is involved in the other Company’s businesses, including manufacturing or purchase and distribution of pharmaceutical products and other consumer health products as well as provision of services, which are the provision of sales, distribution and marketing services to pharmaceutical manufacturers.

Webull offers kinds of HUTCHMED (China) Ltd stock information, including NASDAQ:HCM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HCM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HCM stock methods without spending real money on the virtual paper trading platform.